Abstract
Angiogenesis is critical for tumor growth and metastasis. VEGF is an important mediator of angiogenesis and has emerged as a leading target for cancer therapy. Bevacizumab, a monoclonal antibody to VEGF, has demonstrated improved overall survival when given in combination with carboplatin and paclitaxel in advanced nonsquamous non-small-cell lung cancer. VEGF receptor tyrosine kinase inhibitors are active as monotherapy in advanced non-smallcell lung cancer but have not improved survival when given in combination with chemotherapy. Identification of predictive biomarkers for antiangiogenic agents is a major focus of ongoing investigations. Agents targeting important mediators of angiogenesis are currently being evaluated.
| Original language | English (US) |
|---|---|
| Title of host publication | Advances in Personalized Therapy for Lung Cancer |
| Publisher | Future Medicine Ltd. |
| Pages | 39-51 |
| Number of pages | 13 |
| ISBN (Electronic) | 9781780840345 |
| ISBN (Print) | 9781780841175 |
| DOIs | |
| State | Published - Nov 1 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- General Medicine
Fingerprint
Dive into the research topics of 'Antiangiogenic therapies for non-small-cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver